Re‐admission during · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in re‐admission in compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Asthma severity and symptoms · Adults with acute asthma
1 finding from 1 review
Asthma symptoms Complete resolution by day 28 · Adults with acute asthma
Adults: higher dose/longer course showed no clear difference in asthma symptoms Complete resolution by day 28 compared with lower dose/shorter course (low certainty).
1 finding from 1 review
Exacerbations · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes new exacerbation in compared with lower dose/shorter course (very low certainty).
2 findings from 1 review
FEV1 % predicted · Adults with acute asthma
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
Re‐admission during · children with acute asthma
1 finding from 1 review
Asthma symptoms · children with acute asthma
Children: higher dose/longer course showed no clear difference in asthma symptoms Symptom free by 7 days compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Exacerbations · children with acute asthma
Children: higher dose/longer course showed no clear difference in new exacerbation during compared with lower dose/shorter course (low certainty).
2 findings from 1 review
FEV1 % predicted · children with acute asthma
1 finding from 1 review
All adverse events · children with acute asthma
Children: higher dose/longer course showed no clear difference in all adverse events compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review